|
1
|
Siegel R, Maj Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Creasman WT, Morrow CP, Bundy BN, Homesley
HD, Graham JE and Heller PB: Surgical pathologic spread patterns of
endometrial cancer. A Gynecologic Oncology Group Study. Cancer.
60:2035–2041. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Morrow CP, Bundy BN, Kurman RJ, Creasman
WT, Heller P, Homesley HD and Graham JE: Relationship between
surgical-pathological risk factors and outcome in clinical stage I
and II carcinoma of the endometrium: A gynecologic oncology group
study. Gynecol Oncol. 40:55–65. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Faught W, Krepart GV, Lotocki R and
Heywood M: Should selective paraaortic lymphadenectomy be part of
surgical staging for endometrial cancer? Gynecol Oncol. 55:51–55.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kim YB and Niloff JM: Endometrial
carcinoma: Analysis of recurrence in patients treated with a
strategy minimizing lymph node sampling and radiation therapy.
Obstet Gynecol. 82:175–180. 1993.PubMed/NCBI
|
|
6
|
Orr JW Jr, Holimon JL and Orr PF: Stage I
corpus cancer: Is teletherapy necessary? Am J Obstet Gynecol.
176:777–788; discussion 788–779. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Homesley HD, Kadar N, Barrett RJ and Lentz
SS: Selective pelvic and periaortic lymphadenectomy does not
increase morbidity in surgical staging of endometrial carcinoma. Am
J Obstet Gynecol. 167:1225–1230. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Abu-Rustum NR, Alektiar K, Iasonos A, Lev
G, Sonoda Y, Aghajanian C, Chi DS and Barakat RR: The incidence of
symptomatic lower-extremity lymphedema following treatment of
uterine corpus malignancies: A 12-year experience at memorial
Sloan-Kettering cancer center. Gynecol Oncol. 103:714–718. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cheng WF, Chen CA, Lee CN, Chen TM, Huang
KT, Hsieh CY and Hsieh FJ: Preoperative ultrasound study in
predicting lymph node metastasis for endometrial cancer patients.
Gynecol Oncol. 71:424–427. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
La Fianza A, Di Maggio EM, Preda L, Coscia
D, Tateo S and Campani R: Clinical usefulness of CT in the
treatment of stage I endometrial carcinoma. Radiol Med. 93:567–571.
1997.PubMed/NCBI
|
|
11
|
Frei KA, Kinkel K, Bonél HM, Lu Y,
Zaloudek C and Hricak H: Prediction of deep myometrial invasion in
patients with endometrial cancer: Clinical utility of
contrast-enhanced MR imaging-a meta-analysis and Bayesian analysis.
Radiology. 216:444–449. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cancer Genome Atlas Research Network.
Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H,
Robertson AG, Pashtan I, Shen R, et al: Integrated genomic
characterization of endometrial carcinoma. Nature. 497:67–73. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ohga T, Koike K, Ono M, Makino Y, Itagaki
Y, Tanimoto M, Kuwano M and Kohno K: Role of the human Y
box-binding protein YB-1 in cellular sensitivity to the
DNA-damaging agents cisplatin, mitomycin C and ultraviolet light.
Cancer Res. 56:4224–4228. 1996.PubMed/NCBI
|
|
14
|
Abal M, Llauradó M, Doll A, Monge M, Colas
E, González M, Rigau M, Alazzouzi H, Demajo S, Castellví J, et al:
Molecular determinants of invasion in endometrial cancer. Clin
Transl Oncol. 9:272–277. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Colas E, Perez C, Cabrera S, Pedrola N,
Monge M, Castellvi J, Eyzaguirre F, Gregorio J, Ruiz A, Llaurado M,
et al: Molecular markers of endometrial carcinoma detected in
uterine aspirates. Int J Cancer. 129:2435–2444. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sun P, Xia S, Lal B, Eberhart CG,
Quinones-Hinojosa A, Maciaczyk J, Matsui W, Dimeco F, Piccirillo
SM, Vescovi AL and Laterra J: DNER, an epigenetically modulated
gene, regulates glioblastoma-derived neurosphere cell
differentiation and tumor propagation. Stem Cells. 27:1473–1486.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dewdney SB, Rimel BJ, Thaker PH, Thompson
DM Jr, Schmidt A, Huettner P, Mutch DG, Gao F and Goodfellow PJ:
Aberrant methylation of the X-linked ribosomal S6 kinase RPS6KA6
(RSK4) in endometrial cancers. Clin Cancer Res. 17:2120–2129. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bartman AE, Buisine MP, Aubert JP, Niehans
GA, Toribara NW, Kim YS, Kelly EJ, Crabtree JE and Ho SB: The MUC6
secretory mucin gene is expressed in a wide variety of epithelial
tissues. J Pathol. 186:398–405. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Herbst RS: Review of epidermal growth
factor receptor biology. Int J Radiat Oncol Biol Phys. 59:21–26.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Konecny GE, Santos L, Winterhoff B, Hatmal
M, Keeney GL, Mariani A, Jones M, Neuper C, Thomas B, Muderspach L
and Riehle D: HER2 gene amplification and EGFR expression in a
large cohort of surgically staged patients with nonendometrioid
(type II) endometrial cancer. Br J Cancer. 100:89–95. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ise T, Nagatani G, Imamura T, Kato K,
Takano H, Nomoto M, Izumi H, Ohmori H, Okamoto T, Ohga T, et al:
Transcription factor Y-box binding protein 1 binds preferentially
to cisplatin-modified DNA and interacts with proliferating cell
nuclear antigen. Cancer Res. 59:342–346. 1999.PubMed/NCBI
|
|
22
|
Albitar L, Pickett G, Morgan M, Wilken JA,
Maihle NJ and Leslie KK: EGFR isoforms and gene regulation in human
endometrial cancer cells. Mol Cancer. 9:1662010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chon HS, Marchion DC, Xiong Y, Chen N,
Bicaku E, Stickles XB, Bou Zgheib N, Judson PL, Hakam A,
Gonzalez-Bosquet J, et al: The BCL2 antagonist of cell death
pathway influences endometrial cancer cell sensitivity to
cisplatin. Gynecol Oncol. 124:119–124. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tashiro H, Blazes MS, Wu R, Cho KR, Bose
S, Wang SI, Li J, Parsons R and Ellenson LH: Mutations in PTEN are
frequent in endometrial carcinoma but rare in other common
gynecological malignancies. Cancer Res. 57:3935–3940.
1997.PubMed/NCBI
|
